ResearcherShanghai Jiao Tong UniversityNo recent work listed
Dapeng Xu
Matched on ORCID iD 0000-0003-3319-6364; OpenAlex author ID A5101624302. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 21
2022: 3 papers · 2023: 1 paper
Papers 4
- ADAMTS12 promotes migration and epithelial-mesenchymal transition and predicts poor prognosis for pancreatic cancer. Co-author DOI 10.1016/j.hbpd.2022.04.005↗
- SULF2 enhances GDF15-SMAD axis to facilitate the initiation and progression of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215693↗
- Identification of a novel cell cycle-related risk signature predicting prognosis in patients with pancreatic adenocarcinoma. Co-author DOI 10.1097/md.0000000000029683↗
- Increased SPON1 promotes pancreatic ductal adenocarcinoma progression by enhancing IL-6 trans-signalling. Co-author DOI 10.1111/cpr.13237↗
Closest collaborators
The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Yongwei Sun · 3 shared papers, 2022–2023 · strength 0.45
- Paper ADAMTS12 promotes migration and epithelial-mesenchymal transition and predicts poor prognosis for pancreatic cancer. DOI 10.1016/j.hbpd.2022.04.005↗
- Paper Increased SPON1 promotes pancreatic ductal adenocarcinoma progression by enhancing IL-6 trans-signalling. DOI 10.1111/cpr.13237↗
- Paper SULF2 enhances GDF15-SMAD axis to facilitate the initiation and progression of pancreatic cancer. DOI 10.1016/j.canlet.2022.215693↗
- Dejun Liu · 3 shared papers, 2022–2023 · strength 0.45
- Paper ADAMTS12 promotes migration and epithelial-mesenchymal transition and predicts poor prognosis for pancreatic cancer. DOI 10.1016/j.hbpd.2022.04.005↗
- Paper Increased SPON1 promotes pancreatic ductal adenocarcinoma progression by enhancing IL-6 trans-signalling. DOI 10.1111/cpr.13237↗
- Paper SULF2 enhances GDF15-SMAD axis to facilitate the initiation and progression of pancreatic cancer. DOI 10.1016/j.canlet.2022.215693↗
- Minwei Yang · 3 shared papers, 2022–2023 · strength 0.45
- Paper ADAMTS12 promotes migration and epithelial-mesenchymal transition and predicts poor prognosis for pancreatic cancer. DOI 10.1016/j.hbpd.2022.04.005↗
- Paper Increased SPON1 promotes pancreatic ductal adenocarcinoma progression by enhancing IL-6 trans-signalling. DOI 10.1111/cpr.13237↗
- Paper SULF2 enhances GDF15-SMAD axis to facilitate the initiation and progression of pancreatic cancer. DOI 10.1016/j.canlet.2022.215693↗
- Yan‐Miao Huo · 3 shared papers, 2022–2023 · strength 0.45
- Paper ADAMTS12 promotes migration and epithelial-mesenchymal transition and predicts poor prognosis for pancreatic cancer. DOI 10.1016/j.hbpd.2022.04.005↗
- Paper Increased SPON1 promotes pancreatic ductal adenocarcinoma progression by enhancing IL-6 trans-signalling. DOI 10.1111/cpr.13237↗
- Paper SULF2 enhances GDF15-SMAD axis to facilitate the initiation and progression of pancreatic cancer. DOI 10.1016/j.canlet.2022.215693↗
- Jia-Hao Zheng · 2 shared papers, 2022–2023 · strength 0.32
- Hong‐Fei Yao · 2 shared papers, 2022–2023 · strength 0.32
- Ruizhe He · 2 shared papers, 2022–2023 · strength 0.32
- Jian‐Yu Yang · 2 shared papers, 2022 · strength 0.25
- Xueliang Fu · 2 shared papers, 2022 · strength 0.25
- Wei Chiang Liu · 2 shared papers, 2022 · strength 0.25
- Yingzuo Shi · 1 shared paper, 2022 · strength 0.16
- Li-Peng Hu · 1 shared paper, 2022 · strength 0.13
- Junfeng Zhang · 1 shared paper, 2022 · strength 0.13
- Rong Hua · 1 shared paper, 2022 · strength 0.13
- Juanjuan Shi · 1 shared paper, 2022 · strength 0.12
- Ping Lu · 1 shared paper, 2022 · strength 0.12
- Xuqing Shen · 1 shared paper, 2022 · strength 0.12
- Yongsheng Jiang · 1 shared paper, 2022 · strength 0.12
- Ningning Niu · 1 shared paper, 2022 · strength 0.12
- Jian Yang · 1 shared paper, 2022 · strength 0.12
- Jing Xue · 1 shared paper, 2022 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.